Using a subset of BMD patients (n = 25, age range 6 to 68), we evaluated the association of circulating CXCL10, CCL2, and CCL18, with the Neuro-QoLTM (Quality of Life in Neurological Disorders)-based clinical severity score used to group the patients based on disease progression, symptoms, and ambulation status. This evidence concerns the gene CCL18 and nervous system disorder.